Skip to main content

Atezolizumab in Treating Participants with Asymptomatic Myeloma

Trial Status: Temporarily Closed to Accrual and Intervention

This phase I trial studies how well atezolizumab works in treating participants with asymptomatic myeloma. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of cancer cells to grow and spread.

Inclusion Criteria

  • All patients must sign an Informed Consent Form (ICF) approved by Institutional Review Board, and express ability and willingness to comply with the requirements of the study protocol
  • Patients must meet criteria for high risk asymptomatic myeloma (AMM) defined as: * Bone marrow plasma cells >= 10% and/or levels of monoclonal protein (M-protein) > 3 g/dL and * Abnormal free light chain (FLC) ratio and * Absence of end organ damage (CRAB) defined as: lytic bone lesions on skeletal survey, calcium >= 11 mg/dl, hemoglobin value of > 2 g/100 ml below the lower limit of normal or a hemoglobin value < 10 g/100 ml and renal insufficiency (serum creatinine > 0.173 mmol/l) * Note: Patients with bone marrow plasma cell (BMPC) > 60%, serum free light chain ratio > 100, or known to have 2 or greater focal lesions on magnetic resonance imaging (MRI) and are clinically felt to require therapy will not be included
  • Measurable disease defined by: M-spike > 1 g/dL, or Bence Jones protein > 200 mg/24 hours by urine protein electrophoresis or involved serum free light chain (FLC) > 10 mg/dl
  • Within 28 days prior to the first study treatment (cycle 1, day 1): Absolute neutrophil count (ANC) >= 1500 cells/uL
  • Within 28 days prior to the first study treatment (cycle 1, day 1): White blood cell (WBC) counts > 2500/uL
  • Within 28 days prior to the first study treatment (cycle 1, day 1): Lymphocyte count >= 300/uL
  • Within 28 days prior to the first study treatment (cycle 1, day 1): Platelet count >= 75,000/uL
  • Within 28 days prior to the first study treatment (cycle 1, day 1): Total bilirubin within normal range
  • Within 28 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within normal range
  • Within 28 days prior to the first study treatment (cycle 1, day 1): Serum creatinine within normal range or creatinine clearance >= 60 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of study drug * A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (>= 12 continuous months of menorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus) * Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormonereleasing intrauterine devices, and copper intrauterine devices * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm, as defined below: * With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 5 months after the last dose of study drug. Men must refrain from donating sperm during this same period * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception

Exclusion Criteria

  • Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed: * Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)
  • Adverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopecia
  • Known liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease
  • Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
  • Inability to comply with study and follow-up procedures
  • History of active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes mellitus, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Bell’s palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, glomerulonephritis or autoimmune related dermatologic disease
  • History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.)
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
  • History of human immunodeficiency virus (HIV) infection or known active hepatitis B (chronic or acute) or hepatitis C infection * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
  • Active tuberculosis requiring therapy
  • Severe infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
  • Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
  • Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study * Influenza vaccination should be given during influenza season only. Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study
  • Malignancies other than myeloma within 5 years prior to cycle 1, day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai stage 0, prostate cancer with Gleason score =< 6, and prostate-specific antigen [PSA] =< 10 mg/mL, etc.)
  • MEDICATION-RELATED EXCLUSION
  • Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
  • Treatment with another investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)
  • Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1 * Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled * The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

Connecticut

New Haven
Yale University
Status: TEMPORARILY_CLOSED_TO_ACCRUAL_AND_INTERVENTION
Contact: Noffar Bar
Phone: 203-737-7103

PRIMARY OBJECTIVES:

I. To estimate the prevalence of anti-SOX2 reactive T cells after anti-PDL1 therapy.

SECONDARY OBJECTIVES:

I. To estimate the rate of toxicity of atezolizumab (MPDL3280A).

II. To estimate the objective response rate (>= partial response) after 2, 4 and 8 cycles as well as best response per patient.

III. To assess the association of administration of anti-PDL1 with pharmacodynamics changes in tumor microenvironment (TME).

OUTLINE:

Participants receive atezolizumab intravenously (IV) over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up every 3 months for up to 18 months post study entry.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Yale University

Principal Investigator
Noffar Bar

  • Primary ID 1511016813
  • Secondary IDs NCI-2018-01726
  • Clinicaltrials.gov ID NCT02784483